

3rd November, 2025

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Acquisition of securities in Inzpera Healthsciences Limited

Dear Sir/Madam,

Pursuant to the provisions of the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that Cipla Limited ('the Company') has entered into definitive agreements to acquire 100% stake in Inzpera Healthsciences Limited ('Inzpera'). Upon acquisition, Inzpera will become wholly owned subsidiary of the Company.

The details required to be disclosed under the Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, are enclosed as Annexure I.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode

Annexure - I

Details as per the SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.	<p>Name of the target entity: Inzpera Healthsciences Limited ('Inzpera')</p> <p>Brief Details: Inzpera is a company incorporated in India in the year 2016 and is engaged in the business of developing, manufacturing and marketing of differentiated paediatric pharmaceutical and wellness products.</p> <p>Turnover: Refer point (j)</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
c)	Industry to which the entity being acquired belongs	Pharmaceutical
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The acquisition is a strategic move aimed at combining Inzpera's extensive portfolio of paediatric pharmaceutical and wellness products with the Company's strong distribution network and operational capabilities to drive growth and scalability.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
f)	Indicative time-period for completion of the acquisition	The acquisition is expected to be completed within one month from the date of the signing of the transaction documents or by such other timelines as maybe mutually agreed between the parties.
g)	Nature of consideration - whether cash consideration or share swap and details of the same	Cash

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

h)	Cost of acquisition or the price at which the shares are acquired	The enterprise value of Inzpera as on date is INR 120 crores. After accounting for necessary working capital adjustments, the purchase consideration has been determined to be ~INR 110.65 crores for acquisition of equity shares and non-convertible redeemable preference shares, representing 100% of Inzpera's shareholding. The final consideration remains subject to adjustments on the closing date.
i)	Percentage of shareholding / control acquired and / or number of shares acquired	
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Brief Background: Refer (a) above.</p> <p>History of last 3 years turnover:</p> <p>FY 2024-25: INR 26.75 crores FY 2023-24: INR 22.05 crores FY 2022-23: INR 20.76 crores</p> <p>Date of Incorporation: 22nd June, 2016</p> <p>Country of presence: India</p>

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380